MA62371B1 - Acide nucléique à codons optimisés codant pour la protéine du facteur fix - Google Patents

Acide nucléique à codons optimisés codant pour la protéine du facteur fix

Info

Publication number
MA62371B1
MA62371B1 MA62371A MA62371A MA62371B1 MA 62371 B1 MA62371 B1 MA 62371B1 MA 62371 A MA62371 A MA 62371A MA 62371 A MA62371 A MA 62371A MA 62371 B1 MA62371 B1 MA 62371B1
Authority
MA
Morocco
Prior art keywords
nucleic acid
fix
factor protein
optimized codons
codons coding
Prior art date
Application number
MA62371A
Other languages
English (en)
Other versions
MA62371A1 (fr
Inventor
Dmitry Valentinovich MOROZOV
Anna Nikolaevna STRELKOVA
Pavel Mikhailovich GERSHOVICH
Tatiana Evgenievna SHUGAEVA
Alexander Vladimirovich PROKOFYEV
Natalia Aleksandrovna SPIRINA
Original Assignee
Joint Stock Company "Biocad"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021105703A external-priority patent/RU2831751C2/ru
Application filed by Joint Stock Company "Biocad" filed Critical Joint Stock Company "Biocad"
Publication of MA62371A1 publication Critical patent/MA62371A1/fr
Publication of MA62371B1 publication Critical patent/MA62371B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne les domaines de la génétique, de la thérapie génique et de la biologie moléculaire. Plus particulièrement, la présente invention concerne un acide nucléique isolé à codons optimisés codant pour la protéine FIX (facteur IX de coagulation), une cassette d'expression et un vecteur basé sur cette dernière, ainsi qu'un virus recombiné basé sur l'AAV5 (virus adéno-associé de sérotype 5) pour augmenter l'expression du gène FIX dans des cellules cibles, et son utilisation.
MA62371A 2021-03-05 2022-03-05 Acide nucléique à codons optimisés codant pour la protéine du facteur fix MA62371B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021105703A RU2831751C2 (ru) 2021-03-05 Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение
PCT/RU2022/050073 WO2022186734A1 (fr) 2021-03-05 2022-03-05 Acide nucléique à codons optimisés codant pour la protéine du facteur fix

Publications (2)

Publication Number Publication Date
MA62371A1 MA62371A1 (fr) 2024-03-29
MA62371B1 true MA62371B1 (fr) 2025-12-31

Family

ID=83154378

Family Applications (1)

Application Number Title Priority Date Filing Date
MA62371A MA62371B1 (fr) 2021-03-05 2022-03-05 Acide nucléique à codons optimisés codant pour la protéine du facteur fix

Country Status (20)

Country Link
US (1) US20240076691A1 (fr)
EP (1) EP4288549A4 (fr)
JP (1) JP2024509224A (fr)
KR (1) KR20230154067A (fr)
CN (1) CN117716038A (fr)
AR (1) AR125041A1 (fr)
AU (1) AU2022230548A1 (fr)
BR (1) BR112023018003A2 (fr)
CA (1) CA3212809A1 (fr)
CL (1) CL2023002629A1 (fr)
CO (1) CO2023011679A2 (fr)
CR (1) CR20230429A (fr)
EC (1) ECSP23067213A (fr)
IL (1) IL305679A (fr)
MA (1) MA62371B1 (fr)
MX (1) MX2023010350A (fr)
PE (1) PE20242117A1 (fr)
TW (1) TW202246505A (fr)
UY (1) UY39659A (fr)
WO (1) WO2022186734A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217731A1 (fr) * 2017-05-22 2018-11-29 Baxalta Incorporated Vecteurs viraux codant pour des fix de recombinaison avec une expression accrue pour la thérapie génique de l'hémophilie b
US11008561B2 (en) * 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
EP3270944B1 (fr) * 2015-03-17 2019-10-23 Vrije Universiteit Brussel Systèmes d'expression spécifiques du foie optimisés pour fviii et fix
PL3313991T3 (pl) * 2015-06-23 2024-11-04 The Children's Hospital Of Philadelphia Modyfikowany czynnik ix oraz kompozycje, sposoby i zastosowania do transferu genów do komórek, narządów i tkanek
US11078247B2 (en) * 2016-05-04 2021-08-03 Curevac Ag RNA encoding a therapeutic protein
JP2022505876A (ja) * 2018-10-26 2022-01-14 フリーイェ・ユニヴェルシテイト・ブリュッセル 遺伝子治療を向上させる新しいツール及びその使用
CN113396223A (zh) * 2018-12-06 2021-09-14 比奥维拉迪维治疗股份有限公司 表达因子ix的慢病毒载体的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11008561B2 (en) * 2014-06-30 2021-05-18 Bioverativ Therapeutics Inc. Optimized factor IX gene
WO2018217731A1 (fr) * 2017-05-22 2018-11-29 Baxalta Incorporated Vecteurs viraux codant pour des fix de recombinaison avec une expression accrue pour la thérapie génique de l'hémophilie b

Also Published As

Publication number Publication date
BR112023018003A2 (pt) 2023-12-26
WO2022186734A1 (fr) 2022-09-09
EP4288549A4 (fr) 2025-06-25
MA62371A1 (fr) 2024-03-29
TW202246505A (zh) 2022-12-01
CO2023011679A2 (es) 2024-01-15
AU2022230548A1 (en) 2023-09-28
CN117716038A (zh) 2024-03-15
CA3212809A1 (fr) 2022-09-09
CR20230429A (es) 2024-03-08
KR20230154067A (ko) 2023-11-07
US20240076691A1 (en) 2024-03-07
AR125041A1 (es) 2023-05-31
EP4288549A1 (fr) 2023-12-13
ECSP23067213A (es) 2023-10-31
MX2023010350A (es) 2023-09-22
PE20242117A1 (es) 2024-10-28
IL305679A (en) 2023-11-01
UY39659A (es) 2022-09-30
CL2023002629A1 (es) 2024-04-01
JP2024509224A (ja) 2024-02-29

Similar Documents

Publication Publication Date Title
ZA202213092B (en) Codon-optimized nucleic acid that encodes smn1 protein, and use thereof
CO2021002965A2 (es) Moléculas de ácido nucleico y sus usos para la terapia génica no viral
EA202191418A1 (ru) Рекомбинантные вирусные векторы и нуклеиновые кислоты для их получения
JP2020508685A5 (fr)
SA517390590B1 (ar) Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
PH12022550434A1 (en) Isolated modified vp1 capsid protein of aav5
CR20230363A (es) Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal
BR112022010095A2 (pt) Proteínas gpcr de opsina quimérica
JPWO2021007529A5 (fr)
MA62371B1 (fr) Acide nucléique à codons optimisés codant pour la protéine du facteur fix
MY198257A (en) Gene Therapy With Dysferlin Dual Vectors
MX2021007379A (es) Metodos y composiciones para el tratamiento de enfermedades de almacenamiento de glucogeno.
CL2024000481A1 (es) Proteína de la cápside vp1 modificada aislada de aav9
MX2024002199A (es) Proteina vp1 modificada y aislada de la capside del virus adenoasociado del serotipo 5 (aav5), capside y vector basados en esta.
MX2024013280A (es) Acido nucleico de codon optimizado que codifica la proteina del factor viii de coagulacion de dominio b suprimido, y uso del mismo
MX2024002200A (es) Metodo para obtener una capside de virus adenoasociado modificada.
EA202191148A1 (ru) Рнк, кодирующая белок
NZ748678A (en) Optimized mini-dystrophin genes and expression cassettes and their use